Skip to content
10-Q

Quarterly Report

Bolt Biotherapeutics, Inc. BOLT

0001193125-26-219382

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 1.92M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.68M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.92M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.02M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.37M
Short Term Investments Q1 2026 · Mar 31, 2026 $11.28M
Short Term Investments Q1 2026 · Dec 31, 2025 $15.8M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $11.61M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $11.7M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $8.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $19.82M
Stockholders Equity Q1 2026 · Dec 31, 2025 $26.51M
Stockholders Equity Q1 2026 · Mar 31, 2025 $46.81M
Stockholders Equity Q1 2026 · Dec 31, 2024 $57.2M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.34M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $28.21M
Total Liabilities Q1 2026 · Dec 31, 2025 $30.24M
Current Assets Q1 2026 · Mar 31, 2026 $25.75M
Current Assets Q1 2026 · Dec 31, 2025 $30.26M
Total Assets Q1 2026 · Mar 31, 2026 $48.03M
Total Assets Q1 2026 · Dec 31, 2025 $56.75M
Eps Diluted Q1 2026 · Mar 31, 2026 −$4.31
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$5.76
Eps Basic Q1 2026 · Mar 31, 2026 −$4.31
Eps Basic restated Q1 2026 · Mar 31, 2025 −$5.76
Sga Expense Q1 2026 · Mar 31, 2026 $2.8M
Sga Expense Q1 2026 · Mar 31, 2025 $3.83M
Rd Expense Q1 2026 · Mar 31, 2026 $4.83M
Rd Expense Q1 2026 · Mar 31, 2025 $9.51M
Net Income Q1 2026 · Mar 31, 2026 −$7.24M
Net Income Q1 2026 · Mar 31, 2025 −$11.04M
Operating Income Q1 2026 · Mar 31, 2026 −$7.6M
Operating Income Q1 2026 · Mar 31, 2025 −$12.12M
Revenue Q1 2026 · Mar 31, 2026 $26K
Revenue Q1 2026 · Mar 31, 2025 $1.22M